Synopsis Semaglutide is used as a once-weekly drug approved for the treatment of patients with type 2 diabetes mellitus (T2DM). It is a long-acting GLP-1 analog, whose efficacy and safety have been established through various clinical trials across the continuum of care in T2DM patients. Semaglutide has been compared directly with various antidiabetic drugs and has been studied both as monotherapy and in combination with other agents.
It has consistently shown superior HbA1c and body weight reductions in T2DM patients and has a safety profile similar to that of other GLP-1 receptor agonists. Furthermore, semaglutide significantly reduces the risk of major adverse cardiovascular events in T2DM patients with high cardiovascular risk. The present study aimed to investigate the efficacy and safety of semaglutide when added to SGLT-2 inhibitor therapy in patients with inadequately controlled…
